These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 24432631

  • 1. [Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
    Liu Y.
    Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1147-51. PubMed ID: 24432631
    [Abstract] [Full Text] [Related]

  • 2. Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.
    Ioakeimidis N, Kostis JB.
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):53-64. PubMed ID: 24281316
    [Abstract] [Full Text] [Related]

  • 3. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
    Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH.
    Cardiol Rev; 2007 Jan; 15(2):76-86. PubMed ID: 17303994
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
    Kapur V, Chien CV, Fuess JE, Schwarz ER.
    Rev Cardiovasc Med; 2008 Jan; 9(3):187-95. PubMed ID: 18953278
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.
    Chrysant SG.
    Curr Hypertens Rep; 2013 Oct; 15(5):475-83. PubMed ID: 23917809
    [Abstract] [Full Text] [Related]

  • 10. Tadalafil for the treatment of pulmonary arterial hypertension.
    Klinger JR.
    Expert Rev Respir Med; 2011 Jun; 5(3):315-28. PubMed ID: 21702653
    [Abstract] [Full Text] [Related]

  • 11. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O.
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [Abstract] [Full Text] [Related]

  • 12. Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.
    Cantrell MA, Baye J, Vouri SM.
    Pharmacotherapy; 2013 Jun; 33(6):639-49. PubMed ID: 23529917
    [Abstract] [Full Text] [Related]

  • 13. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
    Arif SA, Poon H.
    Clin Ther; 2011 Aug; 33(8):993-1004. PubMed ID: 21762988
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Endothelial apoptosis decrease following tadalafil administration in patients with arterial ED does not last after its discontinuation.
    La Vignera S, Condorelli RA, Vicari E, D'Agata R, Calogero AE.
    Int J Impot Res; 2011 Aug; 23(5):200-5. PubMed ID: 21677665
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Evaluation of tadalafil for the treatment of erectile dysfunction].
    Liu ZY, Sun YH.
    Zhonghua Nan Ke Xue; 2008 Apr; 14(4):377-80. PubMed ID: 18481436
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
    Rosen RC, McKenna KE.
    Annu Rev Sex Res; 2002 Apr; 13():36-88. PubMed ID: 12836729
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.